Skip to content

Cullinan Therapeutics, Inc. CGEM Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
Amgen logo
AmgenAMGN
-$8M-104%
Janux Therapeutics logo
Janux TherapeuticsJANX
$1.34M+1,552%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$949K-116%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.05M+1,152%
Omeros logo
OmerosOMER
-$87K-118%

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+140%
Enterprise value$1.01B+168%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s change in other assets?
Cullinan Therapeutics, Inc. (CGEM) reported change in other assets of $662K in Q1 2026.
How has Cullinan Therapeutics, Inc.'s change in other assets changed year-over-year?
Cullinan Therapeutics, Inc.'s change in other assets increased by 138.0% year-over-year, from -$1.74M to $662K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.